Guild Biosciences

Guild BioSciences is a division of Guild Associates, Inc., specializing in the development and commercialization of novel bioscience technologies for diagnostics, therapeutics, and specialty biomaterials. The company is a leader in bacteriophage-based solutions, notably its LumiPhage™ platform, which utilizes bioluminescent reporter phages for the rapid and sensitive detection of bacterial pathogens like Bacillus anthracis and Yersinia pestis. Additionally, Guild BioSciences leverages its patented ImmobiZyme™ technology for enzyme immobilization, currently being applied to products like I-Debride for nonsurgical burn wound debridement in field care settings. Serving diverse sectors including biodefense, food safety, and clinical research, the company maintains state-of-the-art BSL-2 facilities in Ohio and South Carolina and is supported by significant government R&D funding.